Clinical trials: Left Ventricular Dysfunction Post Myocardial Infarction
Acute Myocardial Infarction
IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction
Of the patients who survive hospitalization after an acute myocardial infarction, ca. 10% die of sudden cardiac death in the following 2 years. The prognosis appears not improved by medication with antiarrhythmics (class I/III).
- Trial name
- NCT00157768
- Testing
- Implantable cardioverter defibrillator
- Where
- Netherlands
- Volunteers
- 900 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Myocardial Infarction
Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction
Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause…
- Trial name
- SEED-MSC (NCT01392105)
- Testing
- Mesenchymal stem cell, Control group
- Where
- 3 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Ventricular Dysfunction, Myocardial Infarction
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle…
- Trial name
- TABMMI (NCT00507468)
- Testing
- Transendocaridal Transplantation of Autologous Bone Marrow
- Where
- 2 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- BioCardia, Inc.
Left Ventricular Dysfunction
Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack.
- Trial name
- NCT00684060
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- The University of Texas Health Science Center, Houston
Myocardial Infarction, Autonomic Nervous System Diseases
Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction
The majority of deaths after myocardial infarction occurs in patients with preserved left ventricular ejection fraction (>35%) for whom no prophylactic strategies exist.
- Trial name
- SMART-MI (NCT02594488)
- Testing
- Medtronic Reveal LINQ implantable cardiac monitor
- Where
- 32 sites in Austria, Germany
- Volunteers
- 400 people
- Sponsor
- LMU Klinikum
Acute Myocardial Infarction
CARISMA : Cardiac Arrhythmias and Risk Stratification After MyoCardial Infarction
The purpose of this study is to assess the incidence of tachy- and bradyarrhythmic episodes in patients with acute myocardial infarction with depressed ventricular function and to determine the predictive value of several…
- Trial name
- NCT00145119
- Where
- Netherlands
- Volunteers
- 312 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Left Ventricular Dysfunction, Acute Myocardial Infarction
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation
- Trial name
- NCT03902067
- Testing
- UC-MSC, Control Group
- Where
- China
- Sponsor
- Shanghai Life Science & Technology
ST Elevation Myocardial Infarction, Ventricular Remodeling
Impact of Ischemic Post-conditioning
Study will investigate \& compare the left ventricular remodeling \& systolic function between two groups of ST-elevation myocardial infarction undergoing primary per-cutaneous coronary intervention applying ischemic…
- Conditions
- ST Elevation Myocardial Infarction, Ventricular Remodeling, Ventricular Dysfunction, Ischemic Reperfusion Injury
- Trial name
- NCT04068116
- Testing
- Primary per-cutaneous coronary intervention
- Volunteers
- 100 people
- Sponsor
- Assiut University
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde
Myocardial Viability in Ischemic Left Ventricular Dysfunction, Prediction for Improvement in Cardiac Function After Revascularization Therapy
The Use of Myocardial Deformation Imaging
Myocardial deformation imaging allows analysis of myocardial viability in ischemic left ventricular dysfunction. This study will evaluate the predictive value of myocardial deformation imaging for improvement in cardiac function…
- Trial name
- NCT00476320
- Testing
- Magnetic Resonance Imaging, Revascularization, Echocardiography with myocardial deformation imaging
- Where
- Germany
- Sponsor
- RWTH Aachen University
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Post MI Left Ventricular Dysfunction
IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)
The purpose of the INSPIRE-ELR study is to characterize arrhythmias in post MI low EF (≤35%) patients in the acute phase (at discharge from hospital after index MI) and chronic phase (at 8-10 weeks after index MI) and to…
- Trial name
- INSPIRE-ELR (NCT01995552)
- Testing
- External Loop Recorder
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Medtronic BRC
Myocardial Infarction With Non-Obstructive Coronary Artery, Myocarditis Acute
Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics
This clinical study examines patients presenting with acute myocardial infarction and no significant coronary artery disease on coronary angiography (MINOCA) and patients with MINOCA-mimics with advanced CMR.
- Conditions
- Myocardial Infarction With Non-Obstructive Coronary Artery, Myocarditis Acute, Takotsubo Cardiomyopathy, Spontaneous Coronary Artery Dissection
- Trial name
- COPE-CMR (NCT06323811)
- Testing
- CMR
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- University of Zurich
AMI, STEMI
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- Conditions
- AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
- Trial name
- DAPAPROTECTOR (NCT05764057)
- Testing
- Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myocardial Infarction, Early Left Ventricular Dysfunction
Alster Stem Cells - Intramyocardial Stem Therapy
Study to assess the efficacy of intramyocardial bone marrow derived mononuclear cell therapy concerning left ventricular ejection fraction as measured by echocardiography.
- Trial name
- NCT00939042
- Testing
- Percutaneous Coronary Intervention, BMNC therapy
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Asklepios proresearch
Left Ventricular Dysfunction
Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration
Evaluative pilot study for safety and feasibility with administration of autologous bone bone marrow derived mononuclear cells by endoventricular catheter into the normal border zone fo the ischemic lesion.
- Trial name
- NCT00938847
- Testing
- PCI
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Asklepios proresearch
Myocardial Infarction, Echocardiography 2D
Left Ventricular Function After Primary Percutaneous Coronary Intervention: Role of Speckle Echocardiography
Recovery of the left ventricular function is variable from one patient to another, thus assessment of cardiac function by measuring left ventricular ejection fraction using echocardiography is the most common in the daily…
- Conditions
- Myocardial Infarction, Echocardiography 2D, Left Ventricular Dysfunction
- Trial name
- NCT04103008
- Testing
- Speckle tracking echocardiography
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Acute Coronary Syndrome, Cardiogenic Shock
Outcome of Patients Treated With IABP
Intra-Aortic Balloon Pumps (IABP) is a widely used and effective left ventricular adjuvant therapy. IABP is an inflatable device placed in the aorta that inflates with diastole and deflates with systole.
- Conditions
- Acute Coronary Syndrome, Cardiogenic Shock, Coronary Artery Disease, Heart Failure
- Trial name
- NCT04405856
- Testing
- Intra Aortic Balloon Pump
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Nanjing Medical University
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals